Drug intelligence / Profile preview

XKH-002

Development stage: Phase 1
Lead developer: Kanova
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

XKH-002 is a recombinant humanized immunoglobulin (IgG4) monoclonal antibody under development for the treatment of solid tumors. It acts as an inhibitor of B7-H4 (also known as V-set domain containing T cell activation inhibitor 1 or B7S1), a member of the B7 family involved in immune checkpoint regulation. By targeting and inhibiting B7-H4, XKH-002 aims to enhance anti-tumor immune responses. The drug is administered intravenously and is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced or metastatic solid tumors. The developer is Suzhou Xinkanghe Biomedical Technology Co., Ltd.

Targets

VTCN1 (V-set domain containing T cell activation inhibitor 1)

Beyond the preview

Go deeper on XKH-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XKH-002.

Explore the full profile